These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 36755576)

  • 1. Cuproptosis-related gene FDX1 as a prognostic biomarker for kidney renal clear cell carcinoma correlates with immune checkpoints and immune cell infiltration.
    Yao Y; Chen H; Lou M; Chen T
    Front Genet; 2023; 14():1071694. PubMed ID: 36755576
    [No Abstract]   [Full Text] [Related]  

  • 2. Multi-omics pan-cancer study of cuproptosis core gene
    Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
    Front Immunol; 2022; 13():981764. PubMed ID: 36605188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
    Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
    Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma.
    Zhang G; Chen X; Fang J; Tai P; Chen A; Cao K
    Front Immunol; 2022; 13():954440. PubMed ID: 36059510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular subtypes based on cuproptosis regulators and immune infiltration in kidney renal clear cell carcinoma.
    Liu A; Li Y; Shen L; Li N; Zhao Y; Shen L; Li Z
    Front Genet; 2022; 13():983445. PubMed ID: 36338990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Cuproptosis-Related Prognostic Model and the Hub Gene
    Zhang K; Yang W; Zhang Z; Ma K; Li L; Xu Y; Qiu J; Yu C; Zhou J; Cai L; Gong Y; Gong K
    J Oncol; 2022; 2022():2124088. PubMed ID: 36536785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of the Prognosis Value and Potential Mechanism of Immune Checkpoints in Renal Clear Cell Carcinoma Microenvironment.
    Liao G; Wang P; Wang Y
    Front Oncol; 2021; 11():720125. PubMed ID: 34336706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma.
    Bian Z; Fan R; Xie L
    Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated analyses reveal the prognostic, immunological features and mechanisms of cuproptosis critical mediator gene FDX1 in KIRC.
    Wang Y; Zhang X; Chen G; Xing Q; Zhu B; Wang X
    Genes Immun; 2023 Aug; 24(4):171-182. PubMed ID: 37430022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.
    Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H
    Front Immunol; 2022; 13():933241. PubMed ID: 36211378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic, Clinicopathological, and Function of Key Cuproptosis Regulator
    Zeng S; Zhang H; Zhang D; Hu X; Song L
    Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cuproptosis gene-related, neural network-based prognosis prediction and drug-target prediction for KIRC.
    Liu Y; Shao Y; Hao Z; Lei X; Liang P; Chang Q; Wang X
    Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38131663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker.
    Zhang C; Zeng Y; Guo X; Shen H; Zhang J; Wang K; Ji M; Huang S
    Front Genet; 2022; 13():923737. PubMed ID: 35991547
    [No Abstract]   [Full Text] [Related]  

  • 14. Cuproptosis-Related MiR-21-5p/FDX1 Axis in Clear Cell Renal Cell Carcinoma and Its Potential Impact on Tumor Microenvironment.
    Xie M; Cheng B; Yu S; He Y; Cao Y; Zhou T; Han K; Dai R; Wang R
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ARPC1B is a novel prognostic biomarker for kidney renal clear cell carcinoma and correlates with immune infiltration.
    Tang YF; Qiao B; Huang YB; Wang M
    Front Mol Biosci; 2023; 10():1202524. PubMed ID: 37795220
    [No Abstract]   [Full Text] [Related]  

  • 16. Confirmation of the predictive function of cuproptosis-related gene FDX1 in clear cell renal carcinoma using qRT-PCR and western blotting.
    Cai C; Zhou K; Jing J; Ren Y; Weng G; Cen D; Wang X; Huang S
    Aging (Albany NY); 2023 Jul; 15(13):6117-6134. PubMed ID: 37432054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma.
    Lu H; Zhou L; Zhang B; Xie Y; Yang H; Wang Z
    Front Med (Lausanne); 2022; 9():939776. PubMed ID: 36523779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential of targeting cuproptosis in the treatment of kidney renal clear cell carcinoma.
    Lei G; Tang L; Yu Y; Bian W; Yu L; Zhou J; Li Y; Wang Y; Du J
    Biomed Pharmacother; 2023 Nov; 167():115522. PubMed ID: 37757497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of cuproptosis-related gene FDX1 in relation to good prognosis and immune cells infiltration in colon adenocarcinoma (COAD).
    Wang L; Cao Y; Guo W; Xu J
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):15-24. PubMed ID: 36173462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance and immune landscape of cuproptosis-related lncRNAs in kidney renal clear cell carcinoma: a bioinformatical analysis.
    Li D; Wu X; Song W; Cheng C; Hao L; Zhang W
    Ann Transl Med; 2022 Nov; 10(22):1235. PubMed ID: 36544675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.